• 1
    Byers PH 1993 Osteogenesis imperfecta. In: RoycePM, SteinmannB (eds.) Connective Tissue and Its Heritable Disorders. Wiley-Liss, New York, NY, USA, pp. 31750.
  • 2
    Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101116.
  • 3
    Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP 1993 Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 45:261264.
  • 4
    Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tato L 1996 Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 129:432439.
  • 5
    Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, Rosenfeld R, Chrousos GP 1993 The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 76:251256.
  • 6
    Marini JC, Bordenick S, Chrousos G 1995 Endocrine aspects of growth deficiency in OI. Connect Tissue Res 31:S55S57.
  • 7
    Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR 1993 Use of insulin-like growth factor-binding protein-2 (IGFBP-2). IGFBP-3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 77:12941299.
  • 8
    Melkko J, Niemi S, Ristelli L, Risteli J 1990 Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36/7:13281332.
  • 9
    Andrade OMA, Garcia-Mayor RV, Gonzales LD, Rodriguez ST, Segura DA, Alvarez-Novoa R, Antelo CJ 1995 Serum insulin-like growth factor (IGF) binding protein-3 and IGF-I levels during childhood and adolescence. Pediatr Res 38:149155.
  • 10
    Crofton PM, Stirling HF, Schonau E, Kelnar CJH 1995 Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin Endocrinol (Oxf) 44:385394.
  • 11
    Cole DEC, Carpenter TO, Gundberg CM 1985 Serum osteocalcin concentrations in children with metabolic bone disease. J Pediatr 106:770776.
  • 12
    Parfitt AM, Drener MK, Glorieux FH, Kanis JA, Malluche H, Meunier PF, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595610.
  • 13
    Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26:103109.
  • 14
    Saggese G, Baroncelli GI, Bertellone S, Cinquanta L, Di Nero G 1993 Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 122:3745.
  • 15
    Rauch F, Travers R, Parfitt AM, Glorieux FH 2000 Static and dynamic histomorphometry in children with osteogenesis imperfecta. Bone 26:581589.
  • 16
    Parfitt AM, Travers R, Rauch F, Glorieux FH 2000 Structural and cellular changes during bone growth in healthy children. Bone 27:487494.
  • 17
    Spiliotis BE, August GP, Hung W 1984 Growth hormone neurosecretory dysfunction. JAMA 251:22232230.
  • 18
    Saggese G, Bertelloni S, Baroncelli GI, Di Nero G 1992 Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 151:764768.
  • 19
    Saggese G, Baroncelli GI, Bertelloni L, Cinquanta L, Di Nero G 1994 Twenty-four hour osteocalcin, carboxyterminal propeptide of type I procollagen, and amino terminal propeptide of type III procollagen rhythms in normal and growth-retarded children. Pediatr Res 35:409415.
  • 20
    Trivedi P, Risteli J, Risteli L, Hindmash PC, Brook CG, Mowat AP 1991 Serum concentrations of type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 30:276280.
  • 21
    Tapanainen P, Knip M, Risteli L, Kemppainen L, Kaar M-L, Risteli J 1997 Collagen metabolites in the prediction of response to GH therapy in short children. Eur J Endocrinol 37:621625.
  • 22
    Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S, Seino Y 1998 Effect of growth hormone therapy in children with achondroplasia: Growth pattern, hypothalamic- pituitary function, and genotype. Eur J Endocrinol 138:275280.
  • 23
    Seino Y, Moriwaki T, Tanaka H, Inoue M, Kanzaki S, Tanaka T, Matsuo N, Niimi H 1999 Molecular defects in achondroplasia and the effects of growth hormone treatment. Acta Paediatr Suppl 428:118120.
  • 24
    Petryk A, Richton S, Sly JP, Blethen SL 1999 The effect of growth hormone treatment on stature in Aarskog syndrome. J Pediatr Endocrinol Metab 12:161165.
  • 25
    Sas TCJ, Keizer-Schrama SM, Stijnen T, Jansen M, Otten Bj, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Sosen JJ, Rongen-Westerlaken C, Drop SL 1999 Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: Results of a randomized dose-response trial. J Clin Endocrinol Metab 84:46074612.
  • 26
    Hochberg Z, Zadik Z 1999 Final height in young women with Turner syndrome after GH therapy: An open controlled study. Eur J Endocrinol 141:218224.
  • 27
    Van den Broeck J, Van Teunenbroek A, Hokken-Koelaga A, Wit J-M, European Study Group 1999 Efficacy of long-term growth hormone treatment in Turner's Syndrome. J Pediatr Endocrinol Metab 12:673676.
  • 28
    Vetter U, Fisher LW, Mintz KP, Koop JB, Tuross N, Termine JD, Robey PG 1991 Osteogenesis imperfecta: Changes in noncollagenous proteins in bone. J Bone Miner Res 6:501505.
  • 29
    Fedarko NS, Robey PG, Vetter U 1995 Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J Bone Miner Res 10:11221129.
  • 30
    Robey PG, Termine JD 1985 Human bone cells in vitro. Calcif Tissue Int 37:453460.
  • 31
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947952.